Kyleena (Levonorgestrel)

Levonorgestrel released from the device binds to progesterone receptors, suppressing the luteinizing hormone surge and preventing ovulation. It also thickens cervical mucus and alters the endometrium, creating an environment that is hostile to sperm and implantation.

The prescribed dose is determined by the health‑care professional. Kyleena contains a total of 19.5 mg of levonorgestrel and is inserted once into the uterus, where it releases a low, steady dose for up to five years.

Kyleena must not be used during an existing pregnancy and is classified as pregnancy category X. Women who become pregnant while using the device should consult their clinician. Limited data suggest it is compatible with breastfeeding, but a health‑care provider should evaluate individual risk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kyleena contains a lower total levonorgestrel dose (19.5 mg) than some alternatives such as Mirena (52 mg), resulting in a slightly smaller uterine size and a five‑year duration of use. Efficacy remains comparable, while the reduced hormone load may lead to fewer systemic side effects for some users.

Kyleena should be stored at room temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme temperatures until the time of insertion by a qualified clinician.

A trained health‑care professional inserts Kyleena through the cervix into the uterine cavity using a specialized inserter. The procedure is performed in a clinical setting, and the device remains in place for up to five years unless removal is required.

Serious but rare complications include uterine perforation during insertion, ectopic pregnancy if contraception fails, and pelvic inflammatory disease or infection. Patients should be advised to seek immediate medical attention if they experience severe abdominal pain, abnormal bleeding or signs of infection.

Kyleena is contraindicated in women who are pregnant, have known or suspected uterine anomalies, active pelvic infection, untreated cervical cancer, or unexplained vaginal bleeding. It should also be avoided in individuals with a history of severe allergic reaction to levonorgestrel or any component of the device.